Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adhesion G protein-coupled receptor G3 |
| Gene Name | ADGRG3 |
| Uniprot | Q86Y34 (Human); Q8R0T6 (Mouse) |
| Synonym | PB99; GPR97; PGR26; G protein-coupled receptor 97; G-protein coupled receptor PGR26; probable G-protein coupled receptor 97 |
| Background | ADGRG3, also known as G-protein coupled receptor 97 (GPR97) or G-protein coupled receptor PGR26, is a protein encoded by the human ADGRG3 gene. As a member of the adhesion GPCR family which is characterized by an extended extracellular region often possessing N-terminal protein modules, ADGRG3 possesses both an exceptionally long extracellular region, characteristic of cell adhesion proteins and an intracellular region reminiscent of other GPCRs. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX311 | NativeExtract™ Human ADGRG3 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX3621K | MemDX™ Membrane Protein Human ADGRG3 Expressed in vitro E.coli expression system, Full Length of Mature Protein | E.coli cell-free | Full length | Detergent |
| MP0478X | MemDX™ Membrane Protein Human ADGRG3 (Adhesion G protein-coupled receptor G3) for Antibody Discovery | Wheat germ cell-free | Full length | N/A |
| Please for more products or customization | ||||
Th***a: Custom ADGRG3 extracellular domain engineering exceeded expectations.
19/Jul/2023
El***n: Expert technical support streamlined our workflow.
03/Feb/2024
ADGRG3 Gene Therapy Development
We provide tailored solutions to meet your specific requirements. Please for more services.
AAV Vector Development for Targeted ADGRG3 Transduction
Creative Biolabs offers AAV vector development services for targeted ADGRG3 transduction. Adeno-associated virus (AAV)-mediated gene delivery systems are increasingly refined to address the spatial regulation of ADGRG3, a G protein-coupled receptor implicated in angiogenesis and tumor progression. For instance, serotype optimization (e.g., AAV9) combined with tissue-specific promoters enables preferential transduction of vascular endothelial cells or tumor-associated stroma. Preclinical studies in xenograft models demonstrate that AAV-delivered ADGRG3 silencing constructs (shRNA) reduce tumor vascularization by >40%, highlighting translational potential. Creative Biolabs' proprietary AAV capsid engineering platform enhances tropism precision, offering bespoke solutions to modulate ADGRG3 expression in complex microenvironments.
ADGRG3 Knockout for Functional Validation
Creative Biolabs offers ADGRG3 knockout services for functional validation. ADGRG3 disruption provides a robust framework for elucidating its role in pathological signaling cascades. Dual RNA designs targeting exon-intron junctions minimize off-target effects while ensuring frameshift mutations. In glioblastoma models, ADGRG3 knockout attenuates MAPK/ERK activation, reducing invasive growth by 60%. Creative Biolabs' in-house screening pipelines integrate phenotypic assays with multiplexed gRNA libraries to identify context-dependent ADGRG3 interactions.
mRNA Transfection for Transient ADGRG3 Overexpression
Creative Biolabs offers mRNA transfection services for transient ADGRG3 overexpression. Lipid nanoparticle (LNP)-encapsulated mRNA platforms enable transient ADGRG3 overexpression to investigate its therapeutic activation in ischemic tissues. Murine hindlimb ischemia models reveal that intramuscular delivery of codon-optimized ADGRG3 mRNA enhances perfusion by 35% within 14 days, correlating with neovascularization. Creative Biolabs' mRNA stabilization technologies mitigate innate immune responses, ensuring reproducible in vivo expression kinetics.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADGRG3 cell therapy. Please for more services.
CAR-T Cell Engineering Targeting ADGRG3+ Tumors
Creative Biolabs offers CAR-T cell engineering services. Chimeric antigen receptor (CAR)-T cells engineered to recognize ADGRG3 epitopes show promise in solid tumors with aberrant receptor expression. A bispecific CAR design targeting both ADGRG3 and PD-L1 enhances tumor infiltration while counteracting immunosuppression. In pancreatic adenocarcinoma models, this approach reduces tumor burden by 70% compared to monotherapy. Creative Biolabs' CAR construct optimization services include scFv affinity maturation and exhaustion-resistant co-stimulatory domains.
iPSC Differentiation for ADGRG3+ Vascular Progenitors
Creative Biolabs offers iPSC differentiation for ADGRG3+ vascular progenitors services. Directed differentiation of iPSCs into ADGRG3-expressing endothelial progenitors offers regenerative potential for ischemic diseases. Small molecule-driven Wnt/β-catenin activation synergizes with hypoxia-mimicking culture conditions, achieving >85% ADGRG3+ cell purity. Transplanted progenitors in myocardial infarction models restore capillary density by 50%, improving cardiac output. Creative Biolabs' differentiation protocols ensure scalability for preclinical-to-clinical transitions.
ADGRG3-Specific T Cell Receptor (TCR) Therapy
Creative Biolabs offers ADGRG3-specific T cell receptor (TCR) development services. TCR-T cells engineered against ADGRG3-derived neoantigens exploit receptor overexpression in tumor cells. High-throughput TCR sequencing identifies clones with nanomolar affinity, while gene-edited PD-1 knockout enhances persistence. In melanoma models, TCR-T cells reduce metastatic lesions by 65% without on-target/off-tumor toxicity. Creative Biolabs' TCR validation platforms incorporate HLA-peptide tetramer assays and 3D tumor spheroid co-cultures.
The molecular complexity of ADGRG3 demands multidisciplinary expertise to unlock its full therapeutic potential. Creative Biolabs' integrated platforms—spanning vector design, gene editing validation, and cell therapy development—provide a strategic edge in this competitive landscape. Please feel free to to schedule a consultation today to access tailored solutions for your ADGRG3-focused pipeline, from target validation to IND-enabling studies.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
